Acute kidney injury in patients with severe COVID-19 in Mexico

• Published in: PloS one 2021-02, Vol.16 (2), p.e0246595-e0246595
• Main Authors: Casas-Aparicio, Gustavo A, León-Rodríguez, Isabel, Alvarado-de la Barrera, Claudia, González-Navarro, Mauricio, Peralta-Prado, Amy B, Luna-Villalobos, Yara, Velasco-Morales, Alejandro, Calderón-Dávila, Natalia, Ormsby, Christopher E, Ávila-Ríos, Santiago
• Format: Article
• Language: English
• Subjects: Acute Kidney Injury - epidemiology; Acute Kidney Injury - mortality; Acute Kidney Injury - virology; Acute renal failure; Biology and Life Sciences; Biomarkers - metabolism; Bronchopulmonary infection; Coronaviruses; COVID-19; COVID-19 - complications; COVID-19 - epidemiology; Damage accumulation; Development and progression; Female; Furosemide; Health risks; Hospital patients; Hospitalization; Humans; Inflammation - complications; Kaplan-Meier Estimate; Kidney diseases; Kidneys; Male; Medicine and Health Sciences; Mercury; Mexico - epidemiology; Middle Aged; Mortality; Obesity; Oxygen; Patients; Pneumonia; Risk Factors; ROC Curve; SARS-CoV-2 - physiology; Severe acute respiratory syndrome; Severe acute respiratory syndrome coronavirus 2; Statistics; Taxonomy; Ventilators; Viral diseases; Viruses
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0246595

Some patients with COVID-19 pneumonia present systemic disease involving multiple systems. There is limited information about the clinical characteristics and events leading to acute kidney injury (AKI). We described the factors associated with the development of AKI and explored the relation of AKI and mortality in Mexican population with severe COVID-19. We retrospectively reviewed the medical records of individuals with severe pneumonia caused by SARS-CoV-2 hospitalized at the largest third-level reference institution for COVID-19 care in Mexico between March and April 2020. Demographic information, comorbidities, clinical and laboratory data, dates of invasive mechanical ventilation (IMV) and hospitalization, mechanical-ventilator settings and use of vasoactive drugs were recorded. Of 99 patients studied, 58 developed AKI (58.6%). The risk factors for AKI were older age (OR = 1.07, 95% CI = 1.01-1.13, p = 0.024); obesity (OR = 6.58, 95% CI = 1.8-24.05, p = 0.040); and the need for IMV (OR = 6.18, CI = 1.29-29.58, p = 0.023). The risk factors for mortality were obesity (OR = 5.57, 95% CI = 1.48-20.93, p = 0.011); requirement of vasoactive drugs on admission (OR = 5.35, 95% CI = 1.16-24.61, p = 0.031); and AKI (OR = 8.61, 95% CI = 2.24-33.1, p = 0.002). In-hospital mortality was significantly higher in patients with AKI stage 3 (79.3%) and AKI stage 2 (68.7%) compared with those with AKI stage 1 (25%; p = 0.004). Fifty-three patients underwent the furosemide stress test (FST) to predict progression to AKI stage 3. Of those, 12 progressed to AKI stage 3 (22%). The ROC curve for the FST had an AUC of 0.681 (p = 0.009); a sensitivity of 81.6% and a specificity of 54.5%. AKI was common in our cohort of patients with severe pneumonia caused by SARS-CoV-2 infection. The risk factors for AKI were older age, obesity and the need for of IMV on admission. The risk factors for mortality were obesity, requirement of vasoactive drugs on admission and AKI. Mortality was more frequent in patients with AKI stages 2-3. The FST had an acceptable predictive capacity to identify patients progressing to AKI stage 3.